Literature DB >> 12611785

Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study.

Jan Scott1, Stephen Palmer, Eugene Paykel, John Teasdale, Hazel Hayhurst.   

Abstract

BACKGROUND: There is a lack of data on the cost-effectiveness of relapse prevention in depression.
METHOD: A total of 158 subjects with partially remitted major depression despite adequate clinical treatment were randomly allocated to cognitive therapy in addition to antidepressants and clinical management v. antidepressants and clinical management alone. Relapse rates and health care resource utilisation were measured prospectively over 17 months.
RESULTS: Cumulative relapse rates in the cognitive therapy group were significantly lower than in the control group (29% v. 47%). The incremental cost incurred in subjects receiving cognitive therapy over 17 months (pound sterling 779; 95% CI pound sterling 387- pound sterling 1170) was significantly lower than the overall mean costs of cognitive therapy (pound sterling 1164; 95% CI pound sterling 1084- pound sterling 1244). The incremental cost-effectiveness ratio ranged from pound sterling 4328 to pound sterling 5027 per additional relapse prevented.
CONCLUSIONS: In individuals with depressive symptoms that are resistant to standard treatment, adjunctive cognitive therapy is more costly but more effective than intensive clinical treatment alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611785     DOI: 10.1192/bjp.182.3.221

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  13 in total

Review 1.  Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review.

Authors:  Ranak B Trivedi; Jason A Nieuwsma; John W Williams
Journal:  J Gen Intern Med       Date:  2010-12-24       Impact factor: 5.128

Review 2.  Problems in measuring the effectiveness of cognitive therapy for pathological gambling.

Authors:  Michael B Walker
Journal:  J Gambl Stud       Date:  2005

3.  Increasing Access to Cognitive-Behavioural Therapy (CBT) for the Treatment of Mental Illness in Canada: A Research Framework and Call for Action.

Authors:  Krista A Payne; Gail Myhr
Journal:  Healthc Policy       Date:  2010-02

Review 4.  New modalities of assessment and treatment planning in depression: the sequential approach.

Authors:  Giovanni A Fava; Elena Tomba
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 5.  Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.

Authors:  Marieke Krol; Jocé Papenburg; Marc Koopmanschap; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

6.  Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial.

Authors:  Ehsan Bahramali; Negar Firouzabadi; Ilnaz Yavarian; Mohammad Reza Hooshangi Shayesteh; Nasrallah Erfani; Ali Alavi Shoushtari; Roja Asadpour
Journal:  Eur J Clin Pharmacol       Date:  2016-06-05       Impact factor: 2.953

7.  Cost-utility and cost-effectiveness of internet-based treatment for adults with depressive symptoms: randomized trial.

Authors:  Lisanne Warmerdam; Filip Smit; Annemieke van Straten; Heleen Riper; Pim Cuijpers
Journal:  J Med Internet Res       Date:  2010-12-19       Impact factor: 5.428

Review 8.  Epilogue: Lessons from the CONVERGE study of major depressive disorder in China.

Authors:  Jonathan Flint; Yiping Chen; Shenxun Shi; Kenneth S Kendler
Journal:  J Affect Disord       Date:  2011-09-28       Impact factor: 4.839

Review 9.  The genetics of major depression.

Authors:  Jonathan Flint; Kenneth S Kendler
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

Review 10.  Psychotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.